SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs gets license to manufacture, market 2-Deoxy-D-Glucose in India

02 Jul 2021 Evaluate

Laurus Labs has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.

Laurus Labs has already applied with CDSCO for emergency use authroisation (EUA) for 2DG. 

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1176.55 12.55 (1.08%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×